Synbio Companies Come to Grips with the One “Omic” that Matters

Episode Summary

Executive Summary: John Cumbers argues synthetic biology is emerging from a biotech winter: AI is accelerating the design of genes, genomes, proteins, and RNA, while major companies are adopting “biostrategies” to decarbonize supply chains and build new products. Despite funding pressure, he sees recovery in investment, stronger pharma partnerships, and growing traction in ag, food, materials, and longevity ahead of SynBioBeta 2025.

Main Topics: AI as a step-change for synthetic biology (Priority: 5/5): Cumbers says AI is transforming biology by enabling predictive design of DNA, RNA, proteins, genes, and genomes, making engineering faster, cheaper, and more scalable. Biology remains hard to engineer, but progress is real (Priority: 5/5): He contrasts synthetic biology with mature engineering fields, arguing biology has improved since the CRISPR era but is still far from being easy, reliable, or affordable to engineer at scale. Corporate adoption of biostrategies (Priority: 4/5): Large technology, consumer, and industrial companies are increasingly viewing biology as a strategic domain for data, AI, and supply-chain decarbonization, with Microsoft cited as a leading example. Biotech winter and capital constraints (Priority: 5/5): Cumbers describes a funding downturn driven by high interest rates and weaker public markets, which has hit platform companies and non-healthcare synthetic biology especially hard. Investment is recovering, but selectively (Priority: 4/5): He argues capital is returning to synbio, especially for therapeutic assets and AI tools, while broader platform technologies remain underfunded because investors want nearer-term revenue. Commercial traction in planetary health, food, and materials (Priority: 4/5): Examples like Pivot Bio, NotCo, Impossible Foods, and Zymochem illustrate where synthetic biology is already reaching markets or field trials, especially in agriculture, food, and sustainable materials. SynBioBeta as a nexus for partnerships (Priority: 3/5): The conference is positioned as a place where pharma, big tech, investors, startups, and researchers meet to form partnerships and identify the next wave of applications.

Key Arguments: AI is not replacing synthetic biology’s mission; it is finally making the mission more achievable by improving the design-test cycle for biological systems. Biology is still not a mature engineering discipline because cells are vastly more complex than houses, apps, or even airplanes. Most near-term value comes from making known biological functions faster, better, and cheaper rather than inventing entirely new biological capabilities. Major companies now need a biostrategy because biology is becoming a strategic input to AI, data generation, supply-chain redesign, and sustainability. The current downturn is cyclical rather than terminal; like past tech winters, it will likely produce new startups, lower-cost incubators, and eventual recovery. Funding is flowing primarily into therapeutics and AI, not platform tools, because investors prefer revenue-generating assets in a high-rate environment. Commercial success in industrial and agricultural synbio depends less on science than on economics, especially the failure to price in fossil-fuel externalities. Planetary health applications in agriculture, food, chemicals, and materials are moving forward, though they are unevenly advanced. SynBioBeta is increasingly shaped by pharma and AI partnerships because those are the areas with the strongest business momentum today.

Data Points: Age of synthetic biology field: ~25 years - Cumbers says the field is approaching 25 years old. Time horizon for engineering a custom molecule: Still about $3M-$10M and 6-12 months of work - He contrasts current biotech development timelines and costs with mature engineering fields. Investment in synthetic biology in 2024: Over $12 billion - From SynBioBeta’s annual investment report. Investment in synthetic biology in the prior year: About $10 billion - Cumbers compares recent-year funding levels. Investment in synthetic biology two years earlier: About $18 billion - He describes the pandemic-era peak. Investment in synthetic biology in 2019: About $7-$8 billion - Used as a pre-pandemic baseline. Investor lunch attendance: Over 40 investors - Conference attendees for the investor luncheon. Capital represented by investor attendees: Over $40 billion AUM - Assets under management represented by attending investors. Startup luncheon attendance: Over 80 startups - Startups attending the conference’s startup luncheon. Conference dates: May 5th through 8th - SynBioBeta 2025 conference in San Jose. NSC report recommended investment: $15 billion over 5 years - National Security Commission on Emerging Biotechnology recommendation to bolster US biotech leadership. Potential market trajectory: 20% CAGR for the next 10 years - The questioner cites a forecast for the sector.

Pivotal Quotes: "“Synthetic biology is not about what you’re making. Synthetic biology is about the way that you are making it.”" — John Cumbers: Defines the field’s core mission and distinguishes it from product categories. "“There’s really only one omics that matters in biology, at least from a business point of view, and that is economics.”" — John Cumbers: Explains why commercial adoption depends on cost competitiveness and externalities. "“It has been a bloodbath in what I’m calling the biotech winter.”" — John Cumbers: Describes the funding downturn and market pain affecting synbio companies.

Implications: AI could materially lower the cost and time needed to engineer biology, but market success will hinge on economics, not just science. Expect more pharma deals, selective recovery in funding, and continued growth where synbio beats fossil-based alternatives on cost and sustainability.